Top-line results from the CrisADe CARE 1 phase 4 trial showed that crisaborole ointment 2% (Eucrisa; Pfizer) was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD).
The CrisADe CARE 1 trial was a multicenter, open label study that evaluated the safety and efficacy of crisaborole ointment 2% in 137 patients aged 3 months to less than 24 months with mild to moderate AD involving at least 5% treatable body surface area (BSA), excluding the scalp. Findings from the study revealed a safety profile similar to that seen in previous clinical trials; full detailed data will be submitted for presentation at a future scientific meeting.
“These results add to the growing body of evidence that underscores the strength of data for crisaborole as a steroid-free, topical treatment option for people with mild to moderate atopic dermatitis. We look forward to discussing the data with regulatory authorities in the future,” said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development.
Crisaborole ointment is a nonsteroidal, topical phosphodiesterase 4 (PDE-4) inhibitor and is currently indicated for patients aged 2 years and older with mild to moderate atopic dermatitis.
For more information visit pfizer.com.
This article originally appeared on MPR